JP2009538386A - 低分子量ヘパリン組成物およびその使用 - Google Patents

低分子量ヘパリン組成物およびその使用 Download PDF

Info

Publication number
JP2009538386A
JP2009538386A JP2009512295A JP2009512295A JP2009538386A JP 2009538386 A JP2009538386 A JP 2009538386A JP 2009512295 A JP2009512295 A JP 2009512295A JP 2009512295 A JP2009512295 A JP 2009512295A JP 2009538386 A JP2009538386 A JP 2009538386A
Authority
JP
Japan
Prior art keywords
lmwh
composition
activity
reh
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009512295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538386A5 (enExample
Inventor
マリック サンダラム
ガネッシュ ベンカタラマン
パトリシア オリバー
イーミン ヤオ
ゼナブ シラジバイ マムワラ
イアン フィエル
イ ウェイ キ
ザチャリー シュリバー
イシャン カピラ
ヌル シデル グナイ
ダニエラ ベッカッティ
ツイホワ リュー
コリン バウアー
イン リー
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2009538386A publication Critical patent/JP2009538386A/ja
Publication of JP2009538386A5 publication Critical patent/JP2009538386A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009512295A 2006-05-25 2007-05-24 低分子量ヘパリン組成物およびその使用 Pending JP2009538386A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80913606P 2006-05-25 2006-05-25
US84957806P 2006-10-04 2006-10-04
US84962806P 2006-10-05 2006-10-05
PCT/US2007/069626 WO2007140231A2 (en) 2006-05-25 2007-05-24 Low molecular weight heparin composition and uses thereof

Publications (2)

Publication Number Publication Date
JP2009538386A true JP2009538386A (ja) 2009-11-05
JP2009538386A5 JP2009538386A5 (enExample) 2010-06-17

Family

ID=38722686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512295A Pending JP2009538386A (ja) 2006-05-25 2007-05-24 低分子量ヘパリン組成物およびその使用

Country Status (7)

Country Link
US (2) US8609632B2 (enExample)
EP (3) EP2447285A3 (enExample)
JP (1) JP2009538386A (enExample)
CN (1) CN101495517B (enExample)
AU (1) AU2007267561B2 (enExample)
CA (1) CA2652205A1 (enExample)
WO (1) WO2007140231A2 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526171A (ja) * 2009-05-05 2012-10-25 サノフイ 新規なアシル化１，６−無水十糖類および抗血栓剤としてのこの使用
JP2012526172A (ja) * 2009-05-05 2012-10-25 サノフイ 新規な硫酸化七糖類および抗血栓剤としてのこの使用
JP2012526173A (ja) * 2009-05-05 2012-10-25 サノフイ 新規な硫酸化八糖類および抗血栓剤としてのこの使用
JP2012526174A (ja) * 2009-05-05 2012-10-25 サノフイ 新規なアシル化十糖類および抗血栓剤としてのこの使用
JP2013527158A (ja) * 2010-04-16 2013-06-27 モメンタ ファーマシューティカルズ インコーポレイテッド 組織標的化方法
JP2015500387A (ja) * 2011-12-19 2015-01-05 ディラフォレッテ アクチエボラゲット 低抗凝固剤ヘパリン
JP2015500388A (ja) * 2011-12-19 2015-01-05 ディラホア アクチエボラゲット 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途
US9212233B2 (en) 2007-11-02 2015-12-15 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US9351992B2 (en) 2007-11-02 2016-05-31 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US9358252B2 (en) 2007-11-02 2016-06-07 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US10017585B2 (en) 2010-06-17 2018-07-10 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
JP2019501263A (ja) * 2015-12-30 2019-01-17 シェンツェン ヘパリンク ファーマスーティカル グループ カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｈｅｐａｌｉｎｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． 硫酸化ヘパリン由来オリゴ糖及びその調製法と施用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575886B2 (en) 2002-03-11 2009-08-18 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
CN101495517B (zh) 2006-05-25 2012-10-10 莫曼塔医药品有限公司 低分子量肝素及其用途
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
EP2242494A4 (en) * 2008-02-20 2013-01-02 Momenta Pharmaceuticals Inc METHODS OF MANUFACTURING LOW MOLECULAR WEIGHT OF HEPARIN COMPOSITIONS
US20100036310A1 (en) * 2008-08-05 2010-02-11 Hillman Robert S Integrated patient management and control system for medication delivery
CN101711771B (zh) * 2008-10-07 2015-12-09 上海喜恩医药科技发展有限公司 一种肝素衍生的多糖混合物及其制法和药物组合物
US8834807B2 (en) * 2009-08-12 2014-09-16 Caliper Life Sciences, Inc. Device and method for improving sample injection and stacking
FR2949114B1 (fr) * 2009-08-14 2011-08-26 Sanofi Aventis OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2011031301A2 (en) * 2009-08-28 2011-03-17 Mount Sinai School Of Medicine Of New York University Intrapericardial delivery of periostin
EP2480237A1 (en) * 2009-09-23 2012-08-01 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
KR101763440B1 (ko) 2009-12-03 2017-08-14 옵코 헬스, 인크. 과황산화 이당 제제
ES2817779T3 (es) * 2010-01-19 2021-04-08 Momenta Pharmaceuticals Inc Evaluación de preparaciones de heparina
EP2655421B1 (en) 2010-12-23 2022-02-09 The University of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
WO2012100733A1 (zh) * 2011-01-28 2012-08-02 杭州九源基因工程有限公司 一种基于毛细管电泳的依诺肝素钠精细结构测定方法
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN103059165B (zh) * 2012-12-26 2015-04-29 安徽丰原药业股份有限公司 一种多糖酰化物及其制备方法
CN103204958B (zh) * 2013-04-24 2015-04-01 深圳赛保尔生物药业有限公司 一种低乙醇残留的那曲肝素钙生产工艺
ES2924830T3 (es) 2013-06-17 2022-10-11 Univ North Carolina Chapel Hill Moléculas de heparina reversibles
CN103788232A (zh) * 2013-12-23 2014-05-14 深圳市海普瑞药业股份有限公司 一种硫酸乙酰肝素十糖及其制备方法和应用
CN104193849B (zh) * 2014-08-13 2016-08-17 南京健友生化制药股份有限公司 一种依诺肝素钠的生产方法
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
JP6844890B2 (ja) * 2016-01-07 2021-03-17 藤森工業株式会社 採血管、試薬及びそれらを利用した血液性状分析方法
CN105461831A (zh) * 2016-01-08 2016-04-06 东营天东制药有限公司 一种快速分离快速移动肝素与硫酸皮肤素的方法
RU2641058C1 (ru) * 2016-11-17 2018-01-15 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ профилактики венозной тромбоэмболии у больных раком шейки матки
CN108117614B (zh) * 2016-11-29 2020-09-04 北京碧澄生物科技有限公司 低分子量肝素
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
CN110446511B (zh) 2017-03-10 2024-04-02 北卡罗来纳大学查珀尔希尔分校 短效的基于肝素的抗凝血剂化合物和方法
WO2019010216A1 (en) 2017-07-03 2019-01-10 The University Of North Carolina At Chapel Hill ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES
CN111601603A (zh) 2017-11-03 2020-08-28 北卡罗来纳大学查珀尔希尔分校 具有抗炎活性的硫酸化寡糖
CN112437667B (zh) 2018-06-20 2024-05-28 北卡罗来纳大学查珀尔希尔分校 细胞保护方法和组合物
WO2021007429A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides
US20230241095A1 (en) * 2020-06-12 2023-08-03 Ihp Therapeutics Inc. Partially desulfated heparin for treating coronaviral infections
EP4182452A4 (en) 2020-07-14 2024-07-31 Optimvia, LLC METHOD FOR THE SYNTHESIS OF NON-ANTICOAGULATING HEPARAN SULFATE
CN117295772A (zh) * 2021-05-12 2023-12-26 NexEos生物诊断股份有限公司 生产高分子量肝素化合物的方法
KR20250063537A (ko) * 2023-11-01 2025-05-08 건국대학교 글로컬산학협력단 저분자량 헤파린 및 지질이 결합되어 자가 조립된 나노 입자, 이의 제조방법 및 이의 용도

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62283103A (ja) * 1986-04-30 1987-12-09 ノボ　ノルディスク　アクティーゼルスカブ Ｌｍｗ−ヘパリンの製法
JPH07503496A (ja) * 1992-02-07 1995-04-13 ローン−プーラン・ロレ・ソシエテ・アノニム 硫酸化多糖類，それらの調製法，医薬組成物および使用
JPH09510736A (ja) * 1994-08-29 1997-10-28 デビオファルム ソシエテ アノニム ヘパリンをベースとした抗血栓性で非出血性の組成物と、その調製方法と、治療への利用
WO1998055515A1 (en) * 1997-06-06 1998-12-10 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
JP2003504428A (ja) * 1999-06-30 2003-02-04 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド クロット関連凝固因子を阻害するヘパリン組成物
JP2004504451A (ja) * 2000-07-21 2004-02-12 アベンテイス・フアルマ・ソシエテ・アノニム ヘパリンから誘導した多糖の混合物、その製造方法および、それらを含む医薬品組成
WO2004033503A1 (fr) * 2002-10-10 2004-04-22 Aventis Pharma S.A. Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
WO2005010051A2 (fr) * 2003-07-24 2005-02-03 Aventis Pharma S.A. Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663639B1 (fr) 1990-06-26 1994-03-18 Rhone Poulenc Sante Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
US5707973A (en) * 1991-04-23 1998-01-13 Rhone-Poulenc Rorer S.A. Sulfated polysaccharids for treatment or prevention of thromboses
US5849721A (en) * 1992-02-07 1998-12-15 Rhone-Poulenc Rorer S.A. Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof
US5681733A (en) 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US20010046974A1 (en) * 1997-06-06 2001-11-29 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
US5896789A (en) 1997-10-09 1999-04-27 Chicago Pneumatic Tool Company Ratchet wrench head
JP4226101B2 (ja) 1998-05-12 2009-02-18 株式会社アルバック 静電チャックプレート表面からの基板離脱方法
US20020009782A1 (en) * 1999-06-03 2002-01-24 Daphna Miron Heparin and heparan sulfate derived oligosaccharides and a method for their manufacture
ES2231303T3 (es) 2000-01-10 2005-05-16 Dieter Welzel Heparina con masa molecular media.
JP2003525946A (ja) * 2000-03-08 2003-09-02 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉｉｉおよびその使用
US6608042B2 (en) * 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
DK1319183T3 (da) 2000-09-12 2009-05-18 Massachusetts Inst Technology Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US20030050799A1 (en) * 2001-04-03 2003-03-13 Richard Jay Permission based marketing for use with medical prescriptions
JP2005505537A (ja) * 2001-08-28 2005-02-24 レオ・ファーマ・アクティーゼルスカブ 低分子量ヘパリンと低分子量デルマタン硫酸とを含む抗血栓組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US7575886B2 (en) 2002-03-11 2009-08-18 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CN1268650C (zh) * 2003-12-24 2006-08-09 兆科药业（合肥）有限公司 一种低亚硝酸盐含量的低分子肝素钙的制备方法
RU2295538C2 (ru) 2005-03-01 2007-03-20 Гематологический научный центр РАМН Способ получения гепаринов с низкой молекулярной массой
ATE476657T1 (de) * 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
CN101495517B (zh) 2006-05-25 2012-10-10 莫曼塔医药品有限公司 低分子量肝素及其用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62283103A (ja) * 1986-04-30 1987-12-09 ノボ　ノルディスク　アクティーゼルスカブ Ｌｍｗ−ヘパリンの製法
JPH07503496A (ja) * 1992-02-07 1995-04-13 ローン−プーラン・ロレ・ソシエテ・アノニム 硫酸化多糖類，それらの調製法，医薬組成物および使用
JPH09510736A (ja) * 1994-08-29 1997-10-28 デビオファルム ソシエテ アノニム ヘパリンをベースとした抗血栓性で非出血性の組成物と、その調製方法と、治療への利用
WO1998055515A1 (en) * 1997-06-06 1998-12-10 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
JP2003504428A (ja) * 1999-06-30 2003-02-04 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド クロット関連凝固因子を阻害するヘパリン組成物
JP2004504451A (ja) * 2000-07-21 2004-02-12 アベンテイス・フアルマ・ソシエテ・アノニム ヘパリンから誘導した多糖の混合物、その製造方法および、それらを含む医薬品組成
WO2004033503A1 (fr) * 2002-10-10 2004-04-22 Aventis Pharma S.A. Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
WO2005010051A2 (fr) * 2003-07-24 2005-02-03 Aventis Pharma S.A. Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013001205; ＳＨＲＩＶＥＲ，Ｚ．　ｅｔ　ａｌ: 'Ｃｌｅａｖａｇｅ　ｏｆ　ｔｈｅ　ａｎｔｉｔｈｒｏｍｂｉｎ　ＩＩＩ　ｂｉｎｄｉｎｇ　ｓｉｔｅ　ｉｎ　ｈｅｐａｒｉｎ　ｂｙ　ｈｅｐａｒｉｎａｓｅｓ　ａｎｄ　ｉｔｓ　ｉｍｐｌｉｃａｔｉｏｎ　ｉｎ　ｔｈｅ　ｇ' Ｐｒｏｃｅｅｄｉｎｇｓ　ｏｆ　ｔｈｅ　Ｎａｔｉｏｎａｌ　Ａｃａｄｅｍｙ　ｏｆ　Ｓｃｉｅｎｃｅｓ　ｏｆ　ｔｈｅ　Ｕｎｉｔｅｄ　Ｓｔａｔｅｓ　ｏｆ　Ａｍｅｒｉｃａ Ｖｏｌ．９７，　Ｎｏ．１９, 2000, ｐ．１０３６５-１０３７０ *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212233B2 (en) 2007-11-02 2015-12-15 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US9358252B2 (en) 2007-11-02 2016-06-07 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US9351992B2 (en) 2007-11-02 2016-05-31 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
JP2012526174A (ja) * 2009-05-05 2012-10-25 サノフイ 新規なアシル化十糖類および抗血栓剤としてのこの使用
JP2012526171A (ja) * 2009-05-05 2012-10-25 サノフイ 新規なアシル化１，６−無水十糖類および抗血栓剤としてのこの使用
JP2012526173A (ja) * 2009-05-05 2012-10-25 サノフイ 新規な硫酸化八糖類および抗血栓剤としてのこの使用
JP2012526172A (ja) * 2009-05-05 2012-10-25 サノフイ 新規な硫酸化七糖類および抗血栓剤としてのこの使用
JP2013527158A (ja) * 2010-04-16 2013-06-27 モメンタ ファーマシューティカルズ インコーポレイテッド 組織標的化方法
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
US10017585B2 (en) 2010-06-17 2018-07-10 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
JP2015500387A (ja) * 2011-12-19 2015-01-05 ディラフォレッテ アクチエボラゲット 低抗凝固剤ヘパリン
JP2015500388A (ja) * 2011-12-19 2015-01-05 ディラホア アクチエボラゲット 二糖繰り返し単位を含んでいる非抗凝固グリコサミノグリカンおよびそれらの医療用途
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
JP2019501263A (ja) * 2015-12-30 2019-01-17 シェンツェン ヘパリンク ファーマスーティカル グループ カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｈｅｐａｌｉｎｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． 硫酸化ヘパリン由来オリゴ糖及びその調製法と施用

Also Published As

Publication number Publication date
AU2007267561A1 (en) 2007-12-06
CA2652205A1 (en) 2007-12-06
EP2404939A3 (en) 2012-03-21
EP2404939A2 (en) 2012-01-11
AU2007267561B2 (en) 2012-05-17
EP2019843A2 (en) 2009-02-04
WO2007140231A2 (en) 2007-12-06
EP2447285A2 (en) 2012-05-02
US8609632B2 (en) 2013-12-17
US20100305022A1 (en) 2010-12-02
US20070287683A1 (en) 2007-12-13
WO2007140231A3 (en) 2008-12-04
CN101495517A (zh) 2009-07-29
CN101495517B (zh) 2012-10-10
EP2447285A3 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
US8609632B2 (en) Low molecular weight heparin composition and uses thereof
JP4828795B2 (ja) 硫酸化多糖類の分析
US9351992B2 (en) Non-anticoagulant polysaccharide compositions
Jandik et al. Accelerated stability studies of heparin
USRE38743E1 (en) Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
US8071569B2 (en) Oxidized heparin fractions and their use in inhibiting angiogenesis
EP0862585A1 (en) Method for controlling o-desulfation of heparin and compositions produced thereby
JP5351770B2 (ja) ビオチンまたはビオチン誘導体との少なくとも１つの共有結合を含む低分子量ヘパリン、これらの作製方法およびそれらの使用。
CA2107365A1 (en) New non-anticoagulant heparin derivatives
EP2242494A1 (en) Methods of making low molecular weight heparin compositions
US5721357A (en) Preparation of sulfated polysaccharides for treatment or prevention of thromboses
US20120322760A1 (en) Methods of treatment with a low molecular weight heparin composition
Mousa The low molecular weight heparin, tinzaparin, in thrombosis and beyond
Merchant et al. Effect of very low molecular weight henarin-derived oligosaccharides on lipoprotein lipase release in rabbits
EP1731131A1 (en) Hgf production accelerator containing heparin-like oligosaccharide
JP2010518251A (ja) ビオチンまたはビオチン誘導体との少なくとも１つの共有結合を含むヘパリン、これらの調製方法およびこれらの使用
RU2451515C2 (ru) Композиции гепарина низкой молекулярной массы и их применение
Green The heparins: Basic and clinical aspects
HK1134934A (en) Low molecular weight heparin composition and uses thereof
Hernaningsih et al. Examination of Laboratory for Monitoring Heparin Anticoagulant
Jeske et al. Pharmacologic profile of a low-molecular-weight heparin depolymerized by γ-irradiation
Kouta Comparative Studies on Biochemical and Pharmacological Profiles of Unfractionated Heparins & Their Depolymerized Derivatives from Bovine, Ovine and Porcine Origins
JP2002080371A (ja) プラスミノーゲンアクチベーター活性促進剤
Ma Comparative biochemical and pharmacological studies on heparin-derived oligosaccharides
US20050164983A1 (en) Carboxyl-reduced derivatives of dermatan sulfate, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130626